Therapeutic progress for fibrostenotic Crohn’s disease has been stalled in a paradox: Antifibrotic drugs require endpoints ...
News Medical on MSN
Repurposed drug combination shows strong promise against liver fibrosis
The study shows that this drug pair works far better together than either agent alone, offering a realistic and potentially ...
A research team reports a promising new strategy: combining two already-approved drugs—silybin, a natural liver-protective compound, and carvedilol, a widely used cardiovascular medicine—to powerfully ...
Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...
Incyte Corporation is rated Strong Buy with recent execution driving a 56% stock rally and robust revenue growth. Learn more ...
An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...
Hosted on MSN
How much does California need AI?
This story was originally published by CalMatters. Sign up for their newsletters. The top artificial intelligence and tech companies in California may be swimming in cash for now, but as skepticism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results